Helga Radner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helga Radner has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kazuki Yoshida
Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital
3 shared publications Christine Iannaccone
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis St, Boston MA, 02115
2 shared publicationsDaniel H. Solomon
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA
2 shared publications- Ihsane Hmamouchi
Faculty of Medicine, Health Sciences Research Center (CReSS), International University of Rabat (UIR), Rabat, Morocco
2 shared publications Josef S. Smolen
Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria and
2 shared publicationsMichael Weinblatt
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis St, Boston MA, 02115
2 shared publications
Latest Publications
- 1 October 2015
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 45 (2) , 167-173
Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort
- 1 October 2015
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 45 (2) , 167-173
Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort
- Open Access
- 10 July 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (11) , 2076-2084
The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
Objective. When treating RA patients, remission (REM) or at least low disease activity (LDA) is the ultimate therapeutic goal. The aim of this study was to assess the impact of multimorbidity on achieving REM or LDA. Methods. In a prospective RA cohort, we identified patients initiating any DMARD with follow-up data 1 year after. Treatment effects were measured using the clinical disease activity index (CDAI) and the modified health assessment questionnaire (MHAQ); multimorbidity status was assessed using a counted multimorbidity index (cMMI). The proportion of patients reaching REM or LDA 1 year after DMARD commencement with respect to the cMMI was evaluated. In regression models, we calculated the odds ratio of achieving REM or LDA, and predicted CDAI and MHAQ 1 year after DMARD commencement for various levels of cMMI, adjusting for age, sex, disease duration, serostatus, disease activity at DMARD commencement, number of previous DMARDs, and type of DMARD, steroid and NSAID use. Results. A total of 815 patients started DMARDs; 414 were on the same DMARD after 1 year. The proportion of these patients achieving REM or LDA after 1 year was significantly lower in the patients with higher cMMI, following a linear trend (P < 0.01). After accounting for covariates, the odds ratio for REM associated with each additional morbidity in the cMMI was 0.72 (95% CI 0.55, 0.97) and 0.81 (95% CI 0.70, 0.94) for LDA. One year after DMARD initiation, CDAI (+0.16 per additional morbidity) and MHAQ scores (+0.15 per additional morbidity) were significantly worse (both P < 0.05). Conclusion. Increased multimorbidity negatively affects the therapeutic goal of REM and LDA.
- 10 July 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (11) , 2076-2084
Open AccessThe impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
Objective. When treating RA patients, remission (REM) or at least low disease activity (LDA) is the ultimate therapeutic goal. The aim of this study was to assess the impact of multimorbidity on achieving REM or LDA. Methods. In a prospective RA cohort, we identified patients initiating any DMARD with follow-up data 1 year after. Treatment effects were measured using the clinical disease activity index (CDAI) and the modified health assessment questionnaire (MHAQ); multimorbidity status was assessed using a counted multimorbidity index (cMMI). The proportion of patients reaching REM or LDA 1 year after DMARD commencement with respect to the cMMI was evaluated. In regression models, we calculated the odds ratio of achieving REM or LDA, and predicted CDAI and MHAQ 1 year after DMARD commencement for various levels of cMMI, adjusting for age, sex, disease duration, serostatus, disease activity at DMARD commencement, number of previous DMARDs, and type of DMARD, steroid and NSAID use. Results. A total of 815 patients started DMARDs; 414 were on the same DMARD after 1 year. The proportion of these patients achieving REM or LDA after 1 year was significantly lower in the patients with higher cMMI, following a linear trend (P < 0.01). After accounting for covariates, the odds ratio for REM associated with each additional morbidity in the cMMI was 0.72 (95% CI 0.55, 0.97) and 0.81 (95% CI 0.70, 0.94) for LDA. One year after DMARD initiation, CDAI (+0.16 per additional morbidity) and MHAQ scores (+0.15 per additional morbidity) were significantly worse (both P < 0.05). Conclusion. Increased multimorbidity negatively affects the therapeutic goal of REM and LDA.
- 1 June 2015
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (7) , 1099-1104
Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study
Objective. To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA) in contrast to patients with RA only. Methods. COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only, nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use based on a patient’s cMMI and global region after adjusting for age, disease activity, disease duration, educational level, and previous DMARD therapy. Results. Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each additional morbidity (OR 0.89, 95% CI 0.83–0.96). Similar results were found for TNFi (OR 0.91, 95% CI 0.84–0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05–1.22). No significant change of OR was found for NSAID or corticosteroid use. Conclusion. In this study, the odds of bDMARD use decreases 11% for each additional chronic morbid condition after adjustment for regional differences, disease activity, and other covariates.
- 1 June 2015
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (7) , 1099-1104
Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study
Objective. To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA) in contrast to patients with RA only. Methods. COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only, nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use based on a patient’s cMMI and global region after adjusting for age, disease activity, disease duration, educational level, and previous DMARD therapy. Results. Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each additional morbidity (OR 0.89, 95% CI 0.83–0.96). Similar results were found for TNFi (OR 0.91, 95% CI 0.84–0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05–1.22). No significant change of OR was found for NSAID or corticosteroid use. Conclusion. In this study, the odds of bDMARD use decreases 11% for each additional chronic morbid condition after adjustment for regional differences, disease activity, and other covariates.
- Open Access
- 24 December 2013
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (4) , 775-782
Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?
- 24 December 2013
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (4) , 775-782
Open AccessReview: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?